{"id":24062,"date":"2024-04-29T11:17:56","date_gmt":"2024-04-29T09:17:56","guid":{"rendered":"https:\/\/ggba.swiss\/azure-cell-therapies-firefly-fusion-and-antion-biosciences-receive-fif-support\/"},"modified":"2024-04-29T11:19:56","modified_gmt":"2024-04-29T09:19:56","slug":"azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/","title":{"rendered":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences re\u00e7oivent le soutien du FIF"},"content":{"rendered":"\n<p>Azure Cell Therapies, issue de l&rsquo;Universit\u00e9 de Gen\u00e8ve et dirig\u00e9e par le <a href=\"https:\/\/www.linkedin.com\/in\/m-bilal-fares\">Dr Bilal Fares<\/a>, a re\u00e7u une bourse de CHF 50&rsquo;000 pour acc\u00e9l\u00e9rer le d\u00e9veloppement de th\u00e9rapies cellulaires pour la maladie de Parkinson. Cette initiative repr\u00e9sente une avanc\u00e9e majeure dans le domaine de la m\u00e9decine personnalis\u00e9e et d\u00e9montre le potentiel de la biotechnologie avanc\u00e9e pour relever des d\u00e9fis complexes en mati\u00e8re de sant\u00e9.<\/p>\n\n\n\n<p><a href=\"https:\/\/fireflyfusion.energy\/\">FireFly Fusion<\/a>, cofond\u00e9e par Rustem Ospanov, physicien de longue date au CERN, et Justin Ball, sp\u00e9cialiste de la fusion \u00e0 l&rsquo;EPFL, a \u00e9galement re\u00e7u CHF 50&rsquo;000. Ce financement stimulera leurs efforts de d\u00e9veloppement de la technologie de fusion nucl\u00e9aire, dans le but de cr\u00e9er des solutions \u00e9nerg\u00e9tiques durables et propres. Leurs travaux sur les tokamaks standard pourraient ouvrir la voie \u00e0 une \u00e9nergie de fusion commercialement viable, ce qui constituerait une avanc\u00e9e majeure en termes de durabilit\u00e9 environnementale.<\/p>\n\n\n\n<p><a href=\"https:\/\/antionbio.com\/\">Antion Biosciences<\/a> a re\u00e7u un pr\u00eat d&rsquo;amor\u00e7age de CHF 100&rsquo;000 pour faire avancer ses technologies innovantes d&rsquo;\u00e9dition de g\u00e8nes. Sous la direction de Marco Alessandrini et du directeur financier G\u00e9rald Thom\u00e9, Antion se consacre \u00e0 l&rsquo;am\u00e9lioration de la s\u00e9curit\u00e9 et de l&rsquo;accessibilit\u00e9 des th\u00e9rapies cellulaires et g\u00e9niques pour les maladies complexes, promettant ainsi un impact significatif sur les traitements m\u00e9dicaux.<\/p>\n\n\n\n<p>Le <a href=\"https:\/\/www.fongit.ch\/financing\">FIF<\/a>, soutenu par l&rsquo;\u00c9tat de Gen\u00e8ve, le FONGIT, la Chambre de Commerce de Gen\u00e8ve, le Centre de Commerce International des Nations Unies et l&rsquo;Agence des Nations Unies pour l&rsquo;Environnement, continue \u00e0 soutenir des projets innovants qui s&rsquo;alignent sur les Objectifs de D\u00e9veloppement Durable des Nations Unies.<\/p>\n\n\n\n<p>Ces financements renforcent non seulement la position de Gen\u00e8ve en tant que centre d&rsquo;innovation technologique, mais d\u00e9montrent \u00e9galement l&rsquo;importance des efforts de collaboration pour r\u00e9aliser des avanc\u00e9es significatives dans les secteurs de la sant\u00e9 et de l&rsquo;\u00e9nergie au niveau mondial.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"The Fongit Innovation Fund explained (Q&amp;A with Emmanuel de Watteville)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/aI7yukxRRXI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF), et ont re\u00e7u un financement pour faire avancer leur travail de pionnier dans les domaines de la sant\u00e9 et de l&rsquo;\u00e9nergie.<\/p>\n","protected":false},"author":6,"featured_media":24059,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[850],"tags":[1169,1137,1148,1245,1141,1139],"class_list":["post-24062","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-environnement-affaire","tag-biotech-fr-2","tag-energy-fr-2","tag-financing-fr-2","tag-gene-therapy-fr-2","tag-personalized-medicine-fr-2","tag-sustainability-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF<\/title>\n<meta name=\"description\" content=\"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF\" \/>\n<meta property=\"og:description\" content=\"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-29T09:17:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-29T09:19:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Azure Cell Therapies, FireFly Fusion et Antion Biosciences re\u00e7oivent le soutien du FIF\",\"datePublished\":\"2024-04-29T09:17:56+00:00\",\"dateModified\":\"2024-04-29T09:19:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\"},\"wordCount\":357,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"keywords\":[\"Biotech\",\"Energy\",\"Financing\",\"Gene Therapy\",\"Personalized Medicine\",\"Sustainability\"],\"articleSection\":[\"Environnement d'affaire\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\",\"name\":\"Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"datePublished\":\"2024-04-29T09:17:56+00:00\",\"dateModified\":\"2024-04-29T09:19:56+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg\",\"width\":2360,\"height\":1622,\"caption\":\"Le FIF a une fois de plus d\u00e9montr\u00e9 son engagement \u00e0 promouvoir l'innovation technologique \u00e0 Gen\u00e8ve en accordant un soutien financier important \u00e0 trois projets prometteurs.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Azure Cell Therapies, FireFly Fusion et Antion Biosciences re\u00e7oivent le soutien du FIF\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF","description":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/","og_locale":"fr_FR","og_type":"article","og_title":"Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF","og_description":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).","og_url":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-04-29T09:17:56+00:00","article_modified_time":"2024-04-29T09:19:56+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences re\u00e7oivent le soutien du FIF","datePublished":"2024-04-29T09:17:56+00:00","dateModified":"2024-04-29T09:19:56+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/"},"wordCount":357,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","keywords":["Biotech","Energy","Financing","Gene Therapy","Personalized Medicine","Sustainability"],"articleSection":["Environnement d'affaire"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/","url":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/","name":"Azure Cell, FireFly Fusion et Antion re\u00e7oivent le soutien du FIF","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","datePublished":"2024-04-29T09:17:56+00:00","dateModified":"2024-04-29T09:19:56+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences sont les derniers b\u00e9n\u00e9ficiaires du FONGIT Innovation Fund (FIF).","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/FIF-Geneva-2360x1622-1.jpg","width":2360,"height":1622,"caption":"Le FIF a une fois de plus d\u00e9montr\u00e9 son engagement \u00e0 promouvoir l'innovation technologique \u00e0 Gen\u00e8ve en accordant un soutien financier important \u00e0 trois projets prometteurs."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/azure-cell-therapies-firefly-fusion-et-antion-biosciences-recoivent-le-soutien-du-fif\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Azure Cell Therapies, FireFly Fusion et Antion Biosciences re\u00e7oivent le soutien du FIF"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=24062"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24062\/revisions"}],"predecessor-version":[{"id":24064,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24062\/revisions\/24064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/24059"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=24062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=24062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=24062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}